GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Tolvaptan tablets for ADPKD (JYNARQUE)

Local RX List renal extractBase record retrieved 2026-09-07See the evidence for this drug1 sources available - open source summaries, references and comparisons

JYNARQUE

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (1)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Rxlist source

GlobalRPh RX List - JYNARQUE

Product / population
Adult ADPKD JYNARQUE; indication-specific initiation/titration and renal evidence context, not hyponatremia or a full REMS protocol.
Renal measure
Trial measures differ: estimated CrCl (mL/min) versus CKD-EPI eGFR (mL/min/1.73 m2).

RX mirror: this is not independent corroboration of its underlying label. Check dated-label and formulation limitations.

Renal dosing, restrictions and evidence limits

For adults at risk of rapidly progressing ADPKD, the label starts 45 mg on waking and 15 mg eight hours later, then permits weekly-or-longer titration to 60/30 and 90/30 mg if tolerated. The renal evidence section describes trial entry at estimated CrCl at least 60 or CKD-EPI eGFR 25-65 mL/min/1.73 m2; these study criteria are not a CrCl-based dose-reduction table. Ensure adequate water intake and assess dehydration, sodium, interactions and liver risk. Liver testing is required before therapy, at two and four weeks, monthly for 18 months and every three months thereafter. The source identifies a restricted REMS program. This ADPKD schedule must not be substituted for a hyponatremia regimen or extrapolated into a dialysis protocol.

Source revision: March 2025 | Retrieved: 2026-09-07. Retrieval date is not the revision date.

Source: https://globalrph.com/rx-list/jynarque-drug/

Scope: Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

GlobalRPh RX List

GlobalRPh RX List - JYNARQUE

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Adult ADPKD JYNARQUE; indication-specific initiation/titration and renal evidence context, not hyponatremia or a full REMS protocol.

Renal method: Trial measures differ: estimated CrCl (mL/min) versus CKD-EPI eGFR (mL/min/1.73 m2).
Retrieved: 2026-09-07

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceClinician guide

Only one eligible source version is stored here. No second source is inferred from a reference link. Independent corroboration is still needed.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeGlobalRPh RX List - JYNARQUE
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://globalrph.com/rx-list/jynarque-drug/

Exact product and population

Adult ADPKD JYNARQUE; indication-specific initiation/titration and renal evidence context, not hyponatremia or a full REMS protocol.

RDM36-SCOPE-tolvaptan-jynarque-adpkd · Source section: Selected source product scopeRenal section finder
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - JYNARQUE

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · Adult ADPKD JYNARQUE; indication-specific initiation/titration and renal evidence context, not hyponatremia or a full REMS protocol.

Renal method: Trial measures differ: estimated CrCl (mL/min) versus CKD-EPI eGFR (mL/min/1.73 m2).
Source date: March 2025
Retrieved: 2026-09-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

For adults at risk of rapidly progressing ADPKD, the label starts 45 mg on waking and 15 mg eight hours later, then permits weekly-or-longer titration to 60/30 and 90/30 mg if tolerated. The renal evidence section describes trial entry at estimated CrCl at least 60 or CKD-EPI eGFR 25-65 mL/min/1.73 m2; these study criteria are not a CrCl-based dose-reduction table. Ensure adequate water intake and assess dehydration, sodium, interactions and liver risk. Liver testing is required before therapy, at two and four weeks, monthly for 18 months and every three months thereafter. The source identifies a restricted REMS program. This ADPKD schedule must not be substituted for a hyponatremia regimen or extrapolated into a dialysis protocol.

RDM36-rxlist-tolvaptan-jynarque-adpkd-aeb691e82b-C1 · Source locator: Indications; dosage and liver monitoring; Use in Patients With Renal Impairment.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/jynarque-drug/
Retrieved
2026-09-07
Renal-function method
Trial measures differ: estimated CrCl (mL/min) versus CKD-EPI eGFR (mL/min/1.73 m2).
Source date/version
March 2025
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
99c8af98e086ab0dd546e806013bc7bf0363618ba4a8580ef6aae0215f47c7b5

Provenance and preservation

Additional summaries stored on this page: 0 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/rx-list/jynarque-drug/
Source retrieval
2026-09-07. This is not the source publication or label revision date.
Original source type
rxlist summary
Local text SHA-256
154568af2bb43681b18ee20edbe06645519dcce3dffb0d295a392e385b4db8de
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report